Technologies

For additional information, please contact commercialization@360ip.com.

  • B-Mannanase
    • Download Technology Summary  

      The technology developed by 360ip’s partner relates to a recombinant enzyme with improved properties and yield over conventional products in the market. It addresses the problem of the low rate of production of β-Mannanases directly from Aspergillus niger and the fact that the optimal temperature range does not match the internal temperature of most animals.The key advantages associated with this technology are as follows:

      The β-Mannanase of this invention has higher thermal stability as compared with β-Mannanases obtained from Aspergillus sulphureus and Bacillus subtilis. In addition, its optimal temperature range is closer to the rumen of most animals. The β-Mannanase functions at an optimum pH of 5.0, and has good stability at pH: 3.0-7.0. It easily exerts its function in the stomach (pH of about 3.0) and intestinal tract (pH of about 6.0) of pigs & poultry.

      The technology achieves a yield of more than 75%.

  • Alcohol Sensor
    • Download Technology Summary

      The technology developed by 360ip’s partner provides an improved semiconductor alcohol gas sensor through the use of a novel sensing material. The material is comprised of cadmium sulfide-coated carbon nanotubes, and it is compatible with existing semiconductor alcohol gas sensor manufacturing processes.

      The partner’s alcohol gas sensor provides the following advantages:

      High sensitivity (S=Ra/Rg) value of 6 @ 50-100 ppm.

      High specificity with no response to hydrogen sulfide/methane/ammonia/hydrogen/acetone/ benzene/methylbenzene at 1000ppm.

      Low heating temperature of 250 °C.

      Low heating voltage of 4.5V.

      Fast response time of 10s.

  • Antischistosomal Polypeptide
    • Download Technology Summary

      360ip’s partner has discovered a living polypide membrane-binding short peptide with specific targeting and antischistosomal functions. The peptide fragment (ZL-4) was selected by a bacteriophage 12-peptide library from the pellicle of a schistosoma-tailed living schistosomula. The peptide fragment can be used to prepare antischistosomal compounds as well as produce targeting molecules used to perform specific binding with a schistosoma body membrane. The peptide fragment also has potential applications in the development of diagnostic tests for schistosomiasis.

  • BLV Detection
    • Download Technology Summary

      360ip’s partner technology uses a c143 monoclonal antibody for detecting a bovine individual which has a possibility of onset of bovine leukemia. The technology is safe, cost effective and accurate. The partner’s method for the detection and prediction of the onset of bovine leukemia has the following advantages:

       

      May be applied to a wide variety of cattle.

      Conveniently, rapidly and accurately determines the onset of BLV for a large number of bovine individuals.

      Diagnosis of active BLV and predicting resistance/susceptibility to BLV can be achieved all in one sample.

      Can be performed using any of the fluorescent antibody methods, flow cytometry, ELISA, immune-histological assay and PCR.

      Can measure increases in viral levels in addition to a yes/no determination.

      Can be provided in a freeze-dried form or in a liquid form.

  • Atopic Dermatitis Technology
    • Download Technology Summary

      Current treatments for atopic dermatitis (a chronic inflammatory skin disease) only treat the symptoms and not the root cause of the disease. 360ip’s partner has developed a novel treatment that is able to suppress and inhibit the disease, targeting the root cause rather than just treating symptoms. The compound developed by the partner has the following key advantages:

      Suppresses fibroinflammation by targeting discoidin domain receptor tyrosine kinase

      Current treatments only inhibit inflammation

      Inhibits fibrotic cell migration

      Inhibits focal adhesion & actin stress fiber

      Inhibits cell invasion and Akt1 activation

      Suppresses activated macrophage signaling

  • Honeysuckle Beverage
    • Download Technology Summary

      360ip’s partner has developed a novel technology for a honeysuckle and cassia seed compound beverage that addresses the limitations of current beverage technologies The resulting compound beverage provides the non-diluted benefits of these two ingredients. The partner’s technology provides the following advantages:

      Preserves optimal health benefits of both honeysuckle and cassia seed

      Results in clear and stable beverage (due to the use of microcrystalline cellulose as flocculating agent)

      Achieves high quality and prolonged shelf life (up to 24 months vs. 18 months for competing beverages)

      Eliminates distasteful odor

      Enables large-scale industrial production

      360ip’s partner has developed a novel technology for a honeysuckle and cassia seed compound beverage that addresses the limitations of current beverage technologies The resulting compound beverage provides the non-diluted benefits of these two ingredients. The partner’s technology provides the following advantages:

      Phytochemical Chlorogenic Acid
      Chlorogenic Acid ≥50
      Isochlorogenic Acid ≥6.5
      Flavonoids ≥22
      Anthraquinone ≥13
  • Artificial Blood Vessels/Vascular Grafts
    • Download Technology Summary

      360ip’s Partner developed a technology for artificial blood vessels for use as vascular grafts that is able to withstand the high-pressure environment of arterial flow. Prior to this, no tissue-engineered artificial blood vessels could withstand the high-pressure environment.

      In addition, the artificial blood vessels/vascular grafts developed by 360ip’s Partner have the following advantages:

      Composed of viable tissue that is able to contract in response to hemodynamic forces and chemical stimuli.

      High interconnectivity between pores and an optimal mechanical strength.

      High cell seeding and proliferation efficiencies.

      High and long-term patency rates, high burst strength, low compliance mismatch, lack of thrombogenicity, resistance to infections and off-the-shelf availability.

      Has excellent mechanical properties such as flexibility and elasticity and provides appropriate biodegradation time so that it can be used in manufacturing bio-degradable porous polymeric scaffolds suitable for regeneration of soft tissues such as skin and blood vessels, and medical materials such as medical matrix and wound coverings.

  • Long-Circulation Liposome for Drug Delivery
    • Download Technology Summary

      The 360ip Partner’s invention relates to the preparation method and application of a hydrophobic-modified dextran-modified long-circulating liposome. The novel liposome consists of a phospholipid, cholesterol and hydrophobic-modified dextran.

       

      Compared to existing methods, this long-circulating liposome has the following advantages:

      Long-time circulation: Reduction in the phagocytosis of the liposome by the reticuloendothelial system slows down the clearing speed of the liposome, thus prolonging the residence time in the blood.

      Targeting functionality: As free carboxyl exists on the modified dextran of the invention, the modified dextran can be reacted with targeting groups very conveniently, thereby further improving the active targeting function of the liposome.
      High encapsulation rate: The encapsulation rate to a variety of drugs can be more than 95%.

      Uniformity of liposome: This is achieved by filtering blank liposome suspension by the microporous membrane with the corresponding pore diameter.

      Particle size: The average particle size of novel liposome is 50-200nm.

      Enhanced stability: A part of a hydrophobic chain segment of the hydrophobic-modified dextran enters into a hydrophobic layer of the liposome due to entropy driving, which enhances the stability of the internal structure of the liposome.

      Good re-dispersion capacity: The liposome has uniform dispersion, shape and appearance.

      Low cost: The synthesis method of the modified dextran is simple, feasible and low cost.

      Preservation: The liposome can also be freeze-dried for preservation.

  • Dansyl Molecular Probe
    • Download Technology Summary

      360ip Partner’s invention relates to the synthesis and application of novel dansyl molecular probes used for detecting apoptosis. Generally, dansyls are fluorophores that are used as markers and are conjugated to larger molecular probes. However, 360ip’s Partner has designed novel dansyl molecules that have the ability to act as selective and specific probes for apoptosis. The dansyl probes can be used directly to bind to apoptotic cells, thereby serving the function of a probe and a marker.

      The probes have the following benefits:

      Are organic micro-molecules with relatively simple structures as compared to the probes in current use. Can be synthesized with ease using easily available raw materials. High derivatization can be achieved by changing different functional groups to regulate the biochemical characteristics of the molecular probes.

      Have a fast metabolism in vivo, and thus will clear from the body soon after administration.
      Are simple molecules that are not proteins. This makes them less sticky, and thus non-specific interactions occur less often.

      Selectively bind to the apoptotic cells.

      Are intrinsically fluorescent and there is no need to label them.

  • Polyethylene Glycol Omega-amino Acid
    • Download Technology Summary

      360ip partner’s invention is a novel PEG omega-amino acid structure that allows the PEG to have two ends, one amine termini and one carboxyl termini protected. The amine termini can be activated and conjugated to other chemicals under acidic conditions. The carboxyl termini can be activated and conjugated to other chemicals under alkaline conditions. This enables selective conjugation of the termini to the chemical of interest. This property also has the additional benefit of preventing the amine terminal from reacting with the carboxyl terminal.

      The invention also involves a preparation method for synthesizing PEG omega-amino acid that involves a solid-phase reaction, azidation reaction and Curtius rearrangement reaction. This overcomes the complicated separation and purification in the synthesis of PEG omega-amino acid of the existing methods

      The partner’s technology has the following advantages:

      Moderate reaction conditions

      Short synthetic route (reaction time 35-40 hours)

      Simple separation and purification (column chromatography)Yield of more than 70%

      Purity of ~ 95%

      Materials used are less toxic as compared to epoxy ethane used in conventional PEG compounds

  • Anti-Fibrosis Compound
    • Download Technology Summary

      Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. The causes of fibrosis can be radiation, chemotherapy, burns, or an improper treatment of lymphedema. In fibrosis, the tissues are damaged because the scar-like structures prevent tissue fluid from bringing essential nutrients to the cells. This produces increased toxic waste products surrounding the cells within these tissues. Muscles with significant fibrosis have less strength and flexibility and operate with less efficiency compared to normal muscles.

      The main types of fibrosis are Cystic Fibrosis (CF) and Idiopathic Pulmonary Fibrosis (IPF). The global IPF market was valued at USD 2.0 billion in 2009, and it is expected to increase with a compound annual growth rate of 25.1% from 2009 to 2016. The US market for CF is projected to exceed USD 896 million by 2015.

      The main advantages of the compound in the inventions are as follows:

      Long half life, which implies lesser dosage is needed compared with other compounds

      Much higher relative activity compared to other compounds

      Low relative toxicity and very high safety index